rBIO is a biotech manufacturing platform company developing a proprietary process to improve the production economics of essential peptide drugs.
Our first focus is insulin and expand its platform to a pipeline of peptide biosimilars, and other small biologic opportunities.
rBIO’s strategy is centered on a licensing-first model, enabling qualified partners to adopt its process and support more efficient regional and global manufacturing.
Our story
rBIO was founded to address a critical challenge in medicine: essential drugs remain too expensive, supply-constrained, and difficult to scale because manufacturing is complex and concentrated.
The company began with insulin, one of the world’s most widely used peptide drugs.
Today, under the leadership of Dr. Deen Bakthavatsalam, CEO and founder, rBIO is advancing its proprietary manufacturing process toward commercial-scale readiness and licensing.
Cameron Owen, founder, established rBIO’s original business plan and early development path.
rBIO is building the future of scalable peptide manufacturing.
Our mission
To improve the economics of essential peptide drug manufacturing through a scalable, proprietary process that can be licensed to qualified partners worldwide.
Our approach
rBIO combines process innovation, manufacturing know-how, and a licensing-first business model to support more efficient production of peptide drugs.
Our first objective is to complete process scale-up and prepare the platform for licensing and partner-enabled commercialization.
Our near-term focus
Complete insulin process scale-up
Prepare the platform for licensing
Build strategic and regional partnerships
Expand into additional peptide drug opportunities over time
Leadership
Dr. Deen Bakthavatsalam — CEO & Co-Founder
Shawn Swaney — CFO
Cameron Owen — Co-Founder
Board of directors
Stuart Douglass — Executive Chair
Dr. Judith Shizuru — Director
Diane Owen — Director
Scott Douglass — Director
Dr. Deen Bakthavatsalam — Director